Showing 1261-1270 of 2532 results for "".
- Tremfya Safe, Effective Across Broad Patient Subpopulations Through 5 Years: Analysishttps://practicaldermatology.com/news/tremfya-safe-effective-across-broad-patient-subpopulations-through-five-years-analysis/2461130/Tremfya® (guselkumab) from the Janssen Pharmaceutical Companies of Johnson & Johnson can provide a consistent, high degree of durable skin clearance through 5 years in a majority of adult patients across broad subpopulations with moderate to severe plaque psoriasis (PsO), based on an
- DefenAge Receives Two US Patents For Melasma and Hair Growthhttps://practicaldermatology.com/news/defenage-receives-two-us-patents-for-melasma-and-hair-growth/2461118/The US Patent and Trademark Office has granted two new patents to Defanage Skincare for the use of Defensin-molecules for topical treatment of hair loss in skin affected by alopecia and of the hyperpigmented lesions of melasma: &l
- First Austrian Skin Cancer Patients Treated with Rhenium-SCT in New Studyhttps://practicaldermatology.com/news/first-austrian-skin-cancer-patients-treated-with-rhenium-sct-in-new-study/2461110/The first Austrian patients have been treated in the global phase IV EPIC-Skin Study (Efficacy of Personalised Irradiation with Rhenium-SCT– for the treatment of non-melanoma skin cancer), according to OncoBeta GmbH. "This is an important step for better u
- Biofrontera Updates Patient Recruitment for Ameluz-PDT Trialhttps://practicaldermatology.com/news/biofrontera-updates-patient-recruitment-for-ameluz-pdt-trial/2461066/Fully 70 percent of the planned 186 patients have been enrolled in Biofrontera Inc.'s phase III clinical study for the treatment of superficial basal cell carcinoma (sBCC) with Ameluz photodynamic therapy (Ameluz-PDT) in combination with the BF-RhodoLED lamp in the U.S, the company repor
- New Patient Satisfaction Data from Dermavant's PSOARING 3 Trial of Tapinarof in Adults with Plaque Psoriasishttps://practicaldermatology.com/news/new-patient-satisfaction-data-from-dermavants-psoaring-3-trial-of-tapinarof-in-adults-with-plaque-psoriasis/2461043/Results from a patient satisfaction questionnaire in the long-term, open-label Phase 3 PSOARING 3 extension study of tapinarof cream 1% once daily for the treatment of plaque psoriasis in adults demonstrated consistent high rates of satisfaction and positive perception of treatment with tapinarof
- DecisionDx-SCC Performs Well as a Risk-Stratification Tool in Patients with High-risk SCChttps://practicaldermatology.com/news/decisiondx-scc-performs-well-as-a-risk-stratification-tool-in-patients-with-high-risk-scc/2461039/Castle Biosciences, Inc’s DecisionDx-SCC can provide significant and independent prognostic value for stratifying metastasis risk in patients with cutaneous squamous cell carcinoma (SCC) with one or more risk factors (high risk), a new study shows. The study appears in&nb
- First Patient Enrolled in Phase 2b Study of Oral Orismilast in Psoriasishttps://practicaldermatology.com/news/first-patient-enrolled-in-phase-2b-study-of-oral-orismilast-in-psoriasis/2461024/The first patient has been enrolled in IASOS, a Phase 2b dose-ranging study evaluating the safety and efficacy of oral orismilast in patients with moderate to severe psoriasis, according to UNION therapeutics. Orismilast is a next generation PDE4 inhibitor with broad anti-inflammatory p
- ASDSA Honorees Recognized for Engagement in Initiatives that Benefit Dermatologic Surgery and Patientshttps://practicaldermatology.com/news/asdsa-honorees-recognized-for-engagement-in-initiatives-that-benefit-dermatologic-surgery-and-patients/2460995/The American Society for Dermatologic Surgery Association (ASDSA) announced the recipients of its annual awards this week during the ASDS / ASDSA Virtual Annual Meeting. ASDSA is proud to recognize its members who contribute significant time and expertise advocating for patient safety,
- Nearly One Third of Lupus Patients Show Low Responses to COVID-19 Vaccineshttps://practicaldermatology.com/news/nearly-one-third-of-lupus-patients-show-low-responses-to-covid-19-vaccines/2460980/Nearly 30 percent of lupus patients with had a low response to the new COVID-19 vaccines, finds research presented at ACR Convergence, the American College of Rheumatology’s annual meeting. Since Phase III clinical trials of COVID-19 vaccines excluded people who take im
- Vivacare Partnership with Asthma and Allergy Network Provides Professional Digital Patient Education Servicehttps://practicaldermatology.com/news/vivacare-partnership-with-asthma-and-allergy-network-provides-professional-digital-patient-education-service/2460956/Through a new partnership, Vivacare and the Asthma and Allergy Network (AAN) will provide a digital patient education service to Vivacare’s 18,000 professional members, including allergists, dermatologists, pediatricians and primary care providers. Personalized “P